


EXAMINER'S AMENDMENT

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:




1. (Currently Amended) A compound of ~~Compounds of the~~ formula I







in which

- X denotes H, or F, Cl, Br, I, CN, OCN, SCN, COR², COOR², CONR²R³, imidazolyl, pyrazolyl, triazolyl or tetrazolyl,
Y denotes -CHR²-CHR²- or -CR²=CR²-,
Q denotes ~~O, OH, NH, NH², NR²R³, C=O, CHOH, CHNH₂, C=NH, CHOR² or CNR²R³,~~
R¹ denotes branched or unbranched alkylcycloalkyl, alkaryl or alkheteroaryl, each of which is mono- or polysubstituted by X,
R² denotes H or linear or branched alkyl or alkaryl,
R³ denotes H or linear or branched alkyl or alkaryl R², and
m and n, independently of one another, denote 1, 2 or 3,
or a salt, racemate, enantiomer or diastereomer thereof or a mixture thereof and salts,
~~solvates, racemates, enantiomers and diastereomers thereof and mixtures thereof in all ratios.~~

- ⁶
~~2.~~ (Currently Amended) A compound, which is of formula I1, I2, I3, I4, I5, I6 or I7 ~~Compounds of the formula I selected from a group consisting of the compounds I1 to I7;~~







17

or a salt thereof.

⁹
2. (Currently Amended) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as medicaments.~~

¹⁰
4. (Currently Amended) A method for antagonizing ~~Compounds of the formula I according to Claim 1 and physiologically acceptable salts and solvates thereof as medicaments having a 5-HT_{2A} receptor, comprising administering to a subject in need thereof an effective amount of a compound of claim 1~~ receptor-antagonistic action.

¹¹
5. (Withdrawn and Currently Amended) A method for treating ~~Medicaments according to Claim 4 for the treatment of psychoses, schizophrenia, depression, a neurological disorder disorders, a memory disorder disorders, Parkinson's disease, anyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder disorders, such as bulimia, a panic attack attacks, anorexia nervosa, a sleeping disorder disorders, such as also sleep apnoea, or of premenstrual syndrome, or a method for the prophylaxis of or and for combating the consequences of cerebral infarction phenomena, such as strokes stroke or and cerebral ischaemia, and/or or a method for positively influencing~~
¹²
~~or~~ obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

¹²
6. (Currently Amended) A pharmaceutical composition, comprising a

⁶
compound of claim 2 and a pharmaceutically acceptable carrier Pharmaceutical composition comprising at least one medicament according to Claim 5 and optionally excipients and/or adjuvants and optionally other active ingredients.

¹³
1. (Withdrawn and Currently Amended) A method for antagonizing Use
of compounds according to Claim 1 and/or of physiologically acceptable salts and solvates thereof for the preparation of a medicament having a 5-HT_{2A} receptor, comprising administering to a subject in need thereof an effective amount of a compound of claim 2⁶
receptor-antagonistic action.

¹⁴
8. (Withdrawn and Currently Amended) A method for treating Use
according to Claim 7 for the preparation of a medicament for the treatment of psychoses, schizophrenia, depression, a neurological disorder disorders, a memory disorder disorders, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, an eating disorder disorders, such as bulimia, a panic attack attacks, anorexia nervosa, a sleeping disorder disorders, such as also sleep apnoea, or of premenstrual syndrome, or a method for the prophylaxis of or and for combating the consequences of cerebral infarction phenomena, such as strokes stroke or and cerebral ischaemia, and/or or a method for positively influencing⁸ obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound of claim 2.

¹⁵
9. (New) A method for treating psychoses, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.




¹⁶
10. (New) A method for treating psychoses, comprising administering to a subject in need thereof an effective amount of a compound of claim ⁶2.




¹⁷
11. (New) A method for treating Parkinson's disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

¹⁸
12. (New) A method for treating Parkinson's disease, comprising ⁶
administering to a subject in need thereof an effective amount of a compound of claim 2.


8
13. (New)

A compound, which is one of the following compounds






or



wherein

| R | R' | R'' |
|-------------------|----------------------------------|-------|
| F | OH | F |
| F | NH ₂ | F |
| OCN | OH | F |
| OCN | N(CH ₃) ₂ | F |
| F | OH | CN |
| F | NH ₂ | CN |
| OCN | OH | CN |
| OCN | N(CH ₃) ₂ | CN |
| COCF ₃ | OH | CN |
| COCF ₃ | NH ₂ | CN or |
| COCF ₃ | N(CH ₃) ₂ | CN |

or



wherein

| R | R' | R'' |
|-------------------|----------------------------------|-------|
| F | OH | F |
| F | NH ₂ | F |
| OCN | OH | F |
| OCN | N(CH ₃) ₂ | F |
| F | OH | CN |
| F | NH ₂ | CN |
| OCN | OH | CN |
| OCN | N(CH ₃) ₂ | CN |
| COCF ₃ | OH | CN |
| COCF ₃ | NH ₂ | CN or |
| COCF ₃ | N(CH ₃) ₂ | CN |

or a salt thereof.

¹⁹
14. (New) A method for treating psychoses, comprising administering to a subject in need thereof an effective amount of a compound of claim 13.

²⁰
15. (New) A method for treating Parkinson's disease, comprising administering to a subject in need thereof an effective amount of a compound of claim 13.

²
16. (New) A compound according to claim 1, wherein
X denotes H, F or CN,

- Y denotes $-\text{CHR}^2-\text{CHR}^2-$ or $-\text{CR}^2=\text{CR}^2-$,
 Q denotes $\text{C}=\text{O}$, CHOH , or CNR^2R^3 ,
 R^1 denotes unbranched alkaryl, which is monosubstituted by X,
 R^2 denotes H or linear alkyl, and
 R^3 denotes H or linear alkyl.

³
 17. (New) A compound according to claim 1, wherein

- X denotes H or F,
 Y denotes $-\text{CHR}^2-\text{CHR}^2-$ or $-\text{CR}^2=\text{CR}^2-$,
 Q denotes $\text{C}=\text{O}$, CHOH , or CNR^2R^3 ,
 R^1 denotes unbranched alkaryl, which is monosubstituted by X,
 R^2 denotes H or linear alkyl, and
 R^3 denotes H or linear alkyl.

⁴
 18. (New) A compound according to claim 1, wherein

- X denotes H, F or CN,
 Y denotes $-\text{CR}^2=\text{CR}^2-$,
 Q denotes CHOH ,
 R^1 denotes unbranched alkaryl, which is monosubstituted by X, wherein aryl is phenyl, and
 R^2 denotes H.

⁵
 19. (New) A compound according to claim 1, wherein

- X denotes H or F,
 Y denotes $-\text{CR}^2=\text{CR}^2-$,
 Q denotes CHOH ,
 R^1 denotes unbranched alkaryl, which is monosubstituted by X, wherein aryl is phenyl, and
 R^2 denotes H.

⁷ ⁶
 20. (New) A compound according to claim 2, which is of formula I7 or a pharmaceutically acceptable salt thereof.